Interactions of buprenorphine and dipotassium clorazepate on anxiety and memory functions in the mouse

Publié le 13 septembre 2011

Lelong-Boulouard et al., Drug and Alcohol Dependence, 2006

  • Titre traduit : Interactions de la buprénorphine et du Clorazépate Dipotassique sur l’anxiété et les fonctions mémorielles de la souris
  • Auteurs : V. Lelong-Boulouard, T. Quentin, F. Moreaux, D. Debruyne, M. Boulouard, A. Coquerel
  • Résumé : Buprenorphine, a partial mu-receptor agonist widely substituted for heroin in the treatment of addiction, is often misused in combination with benzodiazepines. Improved hedonic properties may result, but only at the cost of increased buprenorphine toxicity. In order to elucidate the appeal of the benzodiazepine-buprenorphine combination, the present study looked at its neuropsycho-pharmacological effects on various emotional and cognitive parameters in the mouse. On the basis of previous dose–response studies, the regimen used was buprenorphine 0.3 mg/kg, s.c. plus dipotassiumclorazepate 1, 4 and 16 mg/kg, i.p. Anxiety-like behaviour was assessed using the black and white test box, and memory processes were examined via the spontaneous alternation paradigm in the Y-maze, and passive avoidance tests. Spontaneous locomotor activity was also evaluated. High doses of clorazepate impaired buprenorphine-induced hyperactivity and anxiogenic-like effects. They also increased buprenorphine-induced spontaneous alternation impairment, but did not modify its impact on long-term memory processes. These results suggest that the positive reinforcement experienced with the buprenorphine–benzodiazepine combination may be attributable, at least in part, to an increase in buprenorphine’s sedative effect associated with a decrease in anxiogenicity.
  • Référence : Drug and Alcohol Dependence 85 (2006) 103–113
  • Liens :
    • Résumé sur PubMed
    • Texte intégral sur + (accès restreint aux seuls Centres d’Addictovigilance)
Retour en haut